Nebenwirkungen · Adempas
Adempas 0.15 mg/mL granules for oral suspension · Abschnitt 4.8 · PDF-Seite 34
HOS-129100 · Präparat HOS-096659
Table 3: Adverse reactions reported with riociguat in adult patients in phase III studies (pooled CHEST 1 and PATENT 1 data) MedDRA Very common Common Uncommon System Organ Class Infections and infestations Gastroenteritis Blood and lymphatic Anaemia (incl. respective system disorders laboratory parameters) Nervous system disorders Dizziness, Headache Cardiac disorders Palpitations Vascular disorders Hypotension Respiratory, thoracic and Haemoptysis, Pulmonary mediastinal disorders Epistaxis, haemorrhage* Nasal congestion Gastrointestinal disorders Dyspepsia, Gastritis, Diarrhoea, Gastro-oesophageal reflux Nausea, disease, Vomiting Dysphagia, Gastrointestinal and abdominal pains, Constipation, Abdominal distension General disorders and Oedema administration site peripheral conditions * fatal pulmonary haemorrhage was reported in uncontrolled long term extension studies
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-22T01:00:00Z · SHA-256 3d1a5306a1e99b336747bac1f508fcb4f4b6128739940b8414bff8db32c20c38 · Passage 02d954d1454afd4d995e1aabf6c39735f9b65e1501abc610e0fc3a7e27dd7f7f · Zeichen 1594–3295 im Abschnitt